title: Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study.
abstract: Subnormal levels of testosterone are associated with significant negative health consequences, with higher risks of all-cause and cardiovascular mortality. The numbers of studies reporting on the benefits of normalisation of testosterone is increasing but longer-term data on (elderly) men receiving testosterone treatment are almost nonexistent. In this single-centre, cumulative, prospective, registry study, 115 hypogonadal men (mean age 59.05 years) received injections with testosterone undecanoate in 12-week intervals for up to 10 years. Waist circumference, body weight and mean BMI dropped progressively with statistical significance versus previous year for 7 years and, respectively, 8 years for weight and body mass index. Similarly, fasting glucose displayed a significant decrease after the first year continuing to decrease thereafter. A decline in HbA1c , from 6.4% to 5.6% (mean <6%), was observed from year 2 on, together with a decrease in the ratio of triglycerides:high-density lipoprotein (HDL), a surrogate marker of insulin resistance, with an increase in HDL levels. The total cholesterol:HDL ratio and non-HDL cholesterol declined significantly. A decrease was also observed in systolic and diastolic blood pressure, with a decrease in levels of the inflammation marker C-reactive protein. No major adverse cardiovascular events were observed throughout the study.
authors.affiliation: Institute for Urology and Andrology, Norderstedt, Germany.|Dresden International University, Dresden, Germany.|Gulf Medical University, Ajman, UAE.
authors.forename: A A
authors.initials: AA
authors.lastname: Yassin
authors.affiliation: Department of Human Metabolism, University of Sheffield, Sheffield, UK.
authors.forename: J
authors.initials: J
authors.lastname: Nettleship
authors.affiliation: Institute for Urology and Andrology, Norderstedt, Germany.
authors.forename: Y
authors.initials: Y
authors.lastname: Almehmadi
authors.affiliation: Institute for Urology and Andrology, Norderstedt, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Salman
authors.affiliation: Gulf Medical University, Ajman, UAE.|Global Medical Affairs Andrology, Bayer Pharma, Berlin, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Saad
mesh_terms: D000328:Adult; D000368:Aged; D000728:Androgens / Q000008:administration & dosage* / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002097:C-Reactive Protein / Q000032:analysis / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012042:Registries; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood / Q000378:metabolism; D055105:Waist Circumference / Q000187:drug effects
chemical_list: D000728:Androgens; D001786:Blood Glucose; D008075:Lipoproteins, HDL; D014280:Triglycerides; D013739:Testosterone; D002097:C-Reactive Protein; D002784:Cholesterol; C010792:testosterone undecanoate
keywords: Ageing men; cardiovascular risks; glucose; lipids; long-term treatment; testosterone